**Supplementary Table 3.** Univariable unadjusted hazard ratios and 95% confidence intervals of covariates and liver decompensation

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Hazard ratio (HR)** | **95% Confidence interval (CI) of HR** | ***p*-value** |
| *Histologic covariates* |  |
| Fibrosis stage0-1234 | Reference1.173.3510.64 | Reference0.29-4.681.08-10.404.38-25.86 | 0.820.04<0.01 |
| Lobular inflammation0123 | Reference0.760.950.71 | Reference0.32-1.770.40-2.240.15-3.36 | 0.520.900.67 |
| Portal inflammation012 | Reference2.041.54 | Reference1.08-3.870.46-5.21 | 0.030.48 |
| Steatosis0123 | Reference0.340.170.22 | Reference0.12-1.030.05-0.520.07-0.70 | 0.06<0.01<0.01 |
| Ballooning012 | Reference2.631.88 | Reference1.33-5.210.53-6.66 | <0.010.33 |
| Acidophils01 | Reference0.81 | Reference0.20-3.35 | 0.77 |
| Mallory bodies012 | Reference2.95- | Reference1.56-5.57- | <0.01- |
| Microvesicular fat | 0.85 | 0.21-3.52 | 0.82 |
| NAFLD activity score | 0.96 | 0.79-1.16 | 0.64 |
| *Clinical covariates*  |  |
| Age | 1.06 | 1.03-1.09 | <0.01 |
| BMIUnderweight/NormalOverweightObese | Reference5.372.74 | Reference0.71-40.500.37-20.25 | 0.100.32 |
| GenderMaleFemale | Reference0.89 | Reference0.48-1.66 | 0.71 |
| RaceWhiteAsianBlack | Reference1.151.07 | Reference0.16-8.420.26-4.45 | 0.890.93 |
| EthnicityNon-HispanicHispanic | Reference1.04 | Reference0.51-2.13 | 0.91 |
| SmokerNever smokerFormer smokerCurrent smoker | Reference2.260.63 | Reference1.20-4.240.15-2.71 | <0.010.53 |
| Hypertension | 4.09 | 1.81-9.27 | <0.01 |
| Type 2 diabetes mellitus | 2.17 | 1.14-4.10 | 0.01 |
| Coronary artery disease | 2.34 | 1.04-5.28 | 0.04 |
| Chronic kidney disease | 1.70 | 0.61-4.78 | 0.31 |
| Congestive heart failure  | 1.56 | 0.37-6.47 | 0.54 |
| Obstructive sleep apnea | 0.97 | 0.42-2.20 | 0.93 |
| *Medications* |  |  |  |
| DPP-4 inhibitor | 3.63 | 0.88-15.04 | 0.08 |
| GLP-1 agonist | 2.18 | 0.67-7.08 | 0.20 |
| Metformin | 1.74 | 0.73-4.13 | 0.21 |
| Statin | 1.23 | 0.68-3.32 | 0.32 |